Antidiabetic effect of Ceiba pentandra extract on streptozotocin-induced non-insulin-dependent diabetic (NIDDM) rats

• Published in: African journal of traditional, complementary, and alternative medicines Vol. 4; no. 1; pp. 47 - 54
• Main Authors: Dzeufiet, Paul Désiré D, Ohandja, Dieudonné Y, Tédong, Léonard, Asongalem, Emmanuel Acha, Dimo, Théophile, Sokeng, Selestin D, Kamtchouing, Pierre
• Format: Journal Article
• Language: English
• Published: Nigeria 28.08.2006
• Subjects: Type 2 diabetes; Plant extract; Ceiba pentandra; Streptozotocin
• ISSN: 2505-0044

The aim of this work was to investigate the effect of daily oral administration of root bark methylene chloride/methanol extract of Ceiba pentandra (Linn) in streptozotocin-induced type-2 diabetic rats, and the effect of this treatment on the physiological and metabolic parameters that are related in diabetic animals. The diabetic rats were separated into four groups and each given the following samples by gavage, daily for 28 days: vehicle (diabetic control), Ceiba pentandra extract at the dose of 40 mg/kg, Ceiba pentandra extract at the dose of 75 mg/kg and glibenclamide (5 mg/kg). All the parameters were also determined in healthy (non diabetic) rats for comparison. The methylene chloride/methanol extract of Ceiba pentandra treatment significantly reduced the intake of both food and water as well as the levels of blood glucose, serum cholesterol, triglyceride, creatinine and urea, in comparison with diabetic controls. The treatment also improves impaired glucose tolerance but no effect was observed in the level of hepatic glycogen. The effect of Ceiba pentandra (40 mg/kg) was more prominent when compared to glibenclamide in lowering blood glucose, with the added benefit of considerably reducing serum cholesterol and triglyceride concentrations. The results of this experimental animal study indicated that Ceiba pentandra possesses antidiabetic activity; and thus is capable of ameliorating hyperglycaemia in streptozotocin-induced type-2 diabetic rats and is a potential source for isolation of new orally active agent(s) for anti-diabetic therapy.